The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
Key Takeaways
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction.
- The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
- The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
Read Complete Original Article
Published originally on CNBC Business



